tiprankstipranks
Trending News
More News >
PaySign (PAYS)
NASDAQ:PAYS
US Market

PaySign (PAYS) AI Stock Analysis

Compare
971 Followers

Top Page

PA

PaySign

(NASDAQ:PAYS)

Rating:71Outperform
Price Target:
$7.00
▼(-2.78%Downside)
The most significant factor contributing to PaySign's stock score is its strong financial performance, characterized by robust cash flows and revenue growth. The positive sentiment from the recent earnings call further supports the score. However, high valuation and potential risks in the plasma segment moderate the overall score.
Positive Factors
Business Expansion
Paysign's growth outlook remains very positive driven by its Pharma Patient Affordability business segment and a recent large new business award within the Plasma segment.
Financial Performance
Paysign reported Q1/25 financial results that included a revenue increase of 41% to $18.6 million with a 193.3% increase in adjusted EBITDA to $4.96 million, results were better than consensus expectations.
Market Position
With the addition of new centers, Paysign will be providing donor compensation programs to more than 615 plasma centers across 18 plasma collection companies, increasing the number of centers the company supports by 27% and bringing its U.S. market share to approximately 50%.
Negative Factors
Revenue Decline
Plasma revenue declined 9.2% to $9.4 million due to reduced revenue per plasma center, reduced plasma donations and lower dollars loaded to cards, due to an industry-wide oversupply in plasma inventories.

PaySign (PAYS) vs. SPDR S&P 500 ETF (SPY)

PaySign Business Overview & Revenue Model

Company DescriptionPaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. The company also develops prepaid card programs for corporate incentive and rewards, including consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, it offers and Per Diem/Corporate Expense Payments that allows businesses, and non–profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, the company provides payment claims processing and other administrative services; pharmacy-based voucher and copay, and medical claims and debit-based affordability programs; PaySign Premier, a demand deposit account debit card; and payment solution for source plasma collection centers, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is based in Henderson, Nevada.
How the Company Makes MoneyPaySign generates revenue primarily through fees associated with its prepaid card programs and payment processing services. Key revenue streams include transaction fees, card maintenance fees, and program management fees charged to clients utilizing their card services. Additionally, the company earns revenue from interchange fees, which are collected from merchants when cardholders use their PaySign cards for purchases. Significant partnerships with healthcare companies, corporate clients, and financial institutions also contribute to its earnings, enabling the company to expand its market presence and client base.

PaySign Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 165.68%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong quarter with record revenue growth, significant increases in net income and EBITDA, and exceptional performance in the Patient Affordability business. However, these positive outcomes were tempered by challenges in the plasma segment, which is experiencing revenue declines due to market surplus and efficiency improvements. Despite these challenges, the company's strategic acquisition of Gamma Innovation is expected to enhance future growth and operational efficiency.
Q1-2025 Updates
Positive Updates
Record Revenue Growth
Revenue grew 41% year-over-year to $18.6 million, up from $13.2 million in Q1 of last year.
Significant Increase in Net Income
Net income surged to $2.59 million, a 737% increase over Q1 2024.
Adjusted EBITDA Growth
Adjusted EBITDA jumped 193% to $4.9 million.
Patient Affordability Business Success
Revenues rose 261% year-over-year to $8.6 million, with claims processed growing by more than 160%.
Gamma Acquisition Benefits
The acquisition is expected to add $4 million to $5 million in annual cash flow and has already shown promising operational efficiencies.
Negative Updates
Plasma Segment Revenue Decline
Revenue in the plasma donor compensation segment decreased by 9.2% to $9.4 million from $10.3 million in Q1 2024.
Challenges in Plasma Market
The plasma segment is facing headwinds due to continued source plasma supply surpluses and improved collection efficiencies at the center level.
Company Guidance
In the first quarter of 2025, Paysign, Inc. reported impressive financial results with substantial year-over-year growth in several key metrics. Revenue increased by 41% to $18.6 million compared to $13.2 million in Q1 2024, while net income surged by 737% to $2.59 million. The company's adjusted EBITDA rose by 193% to $4.9 million, and the gross margin expanded over 10 points to 62.9%. The Patient Affordability segment showed exceptional performance with revenues up 261% to $8.6 million, processing claims growth of over 160%, and the addition of 14 new programs. However, the plasma donor compensation segment faced a 9.2% revenue decline, totaling $9.4 million, amid industry headwinds. Paysign's full-year 2025 guidance includes expected revenues between $72 million and $74 million, with net income projected at $6 million to $7 million. Adjusted EBITDA is anticipated to be in the range of $16 million to $17 million. The company forecasts Q2 2025 revenues between $18.5 million and $19 million, with gross profit margins of 63% to 64%.

PaySign Financial Statement Overview

Summary
PaySign demonstrates strong revenue growth and improving operational efficiency. Despite some pressure on net profitability, the company maintains a healthy balance sheet with low leverage and strong cash flows, positioning it well for future growth and stability. However, the relatively low net profit margin and stockholders' equity warrant careful monitoring to ensure long-term financial health.
Income Statement
75
Positive
PaySign showed a strong revenue growth of 23.5% over the past year, indicating a positive trajectory. The gross profit margin stands at 55.1%, which is solid for the industry. However, the net profit margin has decreased to 6.5% from 13.7% last year, indicating some profitability pressure. The EBIT margin has improved to 1.7%, recovering from negative figures in prior years, showing signs of operational improvement.
Balance Sheet
70
Positive
The debt-to-equity ratio is low at 0.1, indicating minimal leverage, which is beneficial for financial stability. Return on equity is 12.5%, showing reasonable profitability relative to shareholder equity. The equity ratio is 17%, which is moderate and suggests a balanced capital structure. However, the stockholders' equity is relatively low compared to total liabilities, indicating potential risk if liabilities increase.
Cash Flow
80
Positive
Operating cash flow increased to $22.9 million, showcasing robust cash generation capabilities. Free cash flow also showed growth, which is a positive sign for future investments and debt servicing. The operating cash flow to net income ratio is high at 6.0, indicating strong cash conversion efficiency. The free cash flow to net income ratio is 5.9, reinforcing the company's strong cash position relative to earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue63.79M58.38M47.27M38.03M29.46M24.12M
Gross Profit35.51M32.20M24.14M20.95M14.71M9.30M
EBITDA11.84M7.02M3.86M3.25M-213.22K-5.79M
Net Income6.09M3.82M6.46M1.03M-2.72M-9.14M
Balance Sheet
Total Assets205.12M179.03M146.60M108.24M84.05M67.83M
Cash, Cash Equivalents and Short-Term Investments6.85M10.77M16.99M9.71M7.39M7.83M
Total Debt2.83M2.93M3.31M3.67M4.01M4.33M
Total Liabilities165.84M148.59M122.11M91.95M71.06M54.60M
Stockholders Equity39.27M30.44M24.49M16.29M12.99M13.24M
Cash Flow
Free Cash Flow1.38M13.46M20.57M21.23M12.55M10.43M
Operating Cash Flow8.67M22.95M27.62M25.32M15.23M13.78M
Investing Cash Flow-11.66M-9.49M-7.05M-4.09M-2.68M-3.34M
Financing Cash Flow-842.03K-466.25K-1.12M0.00192.14K-72.86K

PaySign Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.20
Price Trends
50DMA
3.95
Positive
100DMA
3.19
Positive
200DMA
3.33
Positive
Market Momentum
MACD
0.84
Negative
RSI
88.98
Negative
STOCH
94.49
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAYS, the sentiment is Positive. The current price of 7.2 is above the 20-day moving average (MA) of 5.40, above the 50-day MA of 3.95, and above the 200-day MA of 3.33, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 88.98 is Negative, neither overbought nor oversold. The STOCH value of 94.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PAYS.

PaySign Risk Analysis

PaySign disclosed 28 risk factors in its most recent earnings report. PaySign reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Global and regional economic conditions could harm our business. Q4, 2023

PaySign Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$384.95M64.7218.82%26.77%-13.24%
69
Neutral
$2.40B22.9115.97%14.86%-0.94%
61
Neutral
$297.67M5.9539.27%-1.90%0.05%
59
Neutral
$614.10M57.39%15.76%82.78%
56
Neutral
$3.16B4.94-5.68%5.75%8.05%-41.83%
50
Neutral
$180.79M-60.94%128.83%73.67%
41
Neutral
$33.92M86.76%9.71%-1.97%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PAYS
PaySign
7.20
3.25
82.28%
IMXI
International Money Express
10.09
-10.18
-50.22%
PRTH
Priority Technology Holdings
7.78
3.02
63.45%
KPLT
Katapult Holdings
8.01
-7.56
-48.55%
PAYO
Payoneer
6.85
1.42
26.15%
BKKT
Bakkt Holdings, Inc. Class A
13.95
-4.92
-26.07%

PaySign Corporate Events

Executive/Board ChangesShareholder Meetings
PaySign Stockholders Approve Key Proposals at Annual Meeting
Neutral
May 13, 2025

On May 7, 2025, PaySign held its annual meeting of stockholders to vote on several key proposals. The stockholders elected seven directors to the board, approved executive compensation on a non-binding advisory basis, and decided to hold advisory votes on executive compensation every three years. Additionally, Moss Adams LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (PAYS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on PaySign stock, see the PAYS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025